Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and physiological pathways without original data or systematic review methodology
PubMed 31240613 · doi:10.1007/s13679-019-00355-z
What was done
The authors reviewed literature on the neurohypophysial endocrine system—specifically oxytocin and arginine-vasopressin pathways—evaluating their psychological, neurological, and peripheral metabolic roles to assess their potential as therapeutic targets in obesity and metabolic dysfunction.
What was found
The abstract reports qualitative observations without numerical data or effect sizes: - Copeptin (a surrogate marker for arginine-vasopressin) is positively associated with body mass index and risk of type 2 diabetes. - Plasma oxytocin is decreased in obesity and other conditions of abnormal glucose homeostasis. - Non-classical tissues such as myocytes, hepatocytes, and pancreatic beta-cells respond to oxytocin and vasopressin receptor binding, potentially altering metabolic function. - Modulation of anorexigenic and orexigenic pathways is the primary mechanism affecting body weight regulation.
Why it matters
Understanding the neurohypophysial endocrine system highlights novel multi-system pathways linking appetite control and peripheral tissue metabolism in obesity. However, widespread physiological actions present substantial barriers to direct pharmacological translation.
Limits
This is a narrative review presenting no original empirical data, quantitative findings, confidence intervals, or sample sizes in the abstract. Reported relationships are primarily associative or mechanistic, precluding conclusions about causality or therapeutic efficacy.
Cited by
- supports Circulating vasopressin, measured via copeptin, is elevated in people with obesity.